溃疡性结肠炎抗TNF-α单抗治疗的最新进展  

New progress of anti-TNFα in the treatment of ulcerative colitis

作　　者：王猛[1] 王启之[1] 

机构地区：[1]蚌埠医学院第一附属医院消化内科,安徽蚌埠233000

出　　处：《胃肠病学和肝病学杂志》2016年第4期468-471,共4页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目前关于溃疡性结肠炎(ulcerative colitis,UC)的发病机制尚不十分清楚,多数认为UC的发生与遗传、环境、感染、免疫等因素有关。关于UC的治疗,临床上常用的方法有药物及外科治疗,其中抗肿瘤坏死因子-α单抗(anti-TNFα)生物治疗是目前的研究热点之一,本文就近几年国内外关于UC的抗TNF-α单抗生物治疗新进展作一概述。Recently,the pathogenesis of ulcerative colitis（UC） remains very unclear. The majority think the occurrence of UC is related to factors of hereditary,environment,infection,immune and so on. Medication and surgery are usually used for the treatment of UC. Anti-tumor necrosis factor α（ anti-TNFα） monoclonal antibody biotherapy is one of the research hotspots. This paper will review the new progress of the anti-TNFα antibody biotherapy.

关 键 词：溃疡性结肠炎 生物治疗 英夫利昔 

分 类 号：R574.62[医药卫生—消化系统]